DESIGN & DEVELOPMENT OF NOVEL DRUGS BASED ON A NEW TECHNOLOGY
PIONEERING SOLUTIONS TO
THE GREATEST THREATS IN MODERN MEDICINE
THERE IS AN URGENT
NEED TO COMBAT VIRAL
INFECTIONS THAT CAN
THE WORLD IS HEADING
TO A POST-ANTIBIOTIC
ERA IN WHICH COMMON
INFECTIONS COULD ONCE
AGAIN KILL (WHO)
QBR A/S is a Danish company developing novel Anti Microbial & Anti Viral Peptides as a new class of drugs in infectious diseases.
QBR is at the forefront of the interface of Physics and Chemistry in drug design, utilizing a ground- breaking Resonant Recognition Model – RRM.
PARTNERSHIPS & IP
AMALNA Consulting (AU), RRM Technology.
Loma Linda University Hospital (USA), collaborative reresearch and testing facilities.
Ljubljana University (SLO) collaborative research and Lab level 3 testing facilities.
Pepscan (NL), collaboration agreement regarding development of GMP grade of Peptide Cov18A.
Leukocare (D), development of non-toxic solvents.
QBR has cooperation agreement with all parties and is the owner of the patented IP.
More then 20 years experience as an entrepreneur and as consultant for private sector and universities, developing Innovative companies and research project in bio- physical systems.
Director and founder of AMALNA consulting. Development of RRM model since 1994. Experience in biophysics, biomedical engineering and biomedical signal processing.
25 years research in respiratory viral infections, herpesviruses, avian pathogenics, Covid19 virus, more then 105 scientific papers published regarding viral infections.
PROF. HANSEL FLETCHER
Loma Linda University Hospital, USA.
Microbiology Division; Pharmaceutical Science, molecular genetics and biochemistry of microbial diseases, his research program has been focused on bacterial pathogens and recently resistant bacteria.
PROF. ALEN ALBRETH
National Institute of
Specialising in liquid chromatography
spectrometry, mass spectrometry, complex biological bio fluids,
analytical method development.....